top of page
  • Writer's pictureWendong Chen

Is personalized IL-17A inhibitor treatment needed for patients with severe psoriasis?


Nomine Health collaborates with Xiangya Hospital of Central South University to publish an article titled 'Do Severe Plaque Psoriasis Patients in the Real World Receiving Interleukin-17A Inhibitor Therapy Need Personalized Treatment Strategy?' in the Journal of the European Academy of Dermatology & Venereology (Impact Factor 9.228 in 2021). This study utilized real-world data from Chinese patients with moderate-to-severe plaque psoriasis to evaluate the need for personalized treatment strategies for interleukin-17A inhibitors. The short-term clinical efficacy of interleukin-17A inhibitors in the real world was assessed, and potential factors influencing their clinical efficacy were explored in this study. The study results revealed that patients receiving ixekizumab had significantly higher proportions of age, male gender, metabolic syndrome, hyperlipidemia, and obesity compared to patients receiving secukinumab. The short-term clinical efficacy of the two interleukin-17A inhibitors was comparable, but ixekizumab showed significantly improved patient quality of life outcomes (DLQI) compared to secukinumab. Factors significantly affecting the efficacy of interleukin-17A inhibitors included baseline disease severity, location of skin lesions, white blood cell count, and hyperlipidemia. These findings suggest that when using interleukin-17A inhibitors to treat moderate-to-severe plaque psoriasis in clinical practice, it is essential to consider individual patient characteristics and intervene appropriately before treatment to control factors influencing treatment outcomes and maximize the therapeutic effect of interleukin-17A inhibitors. For more information about this study, please click here.

8 views0 comments


bottom of page